|Mr. Michael Wolff Jensen||Chairman, Sr. VP & Chief Legal Officer||N/A||N/A||1971|
|Mr. Jan Møller Mikkelsen||Pres, CEO, Member of Exec. Board & Exec. Director||N/A||N/A||1960|
|Mr. Scott T. Smith||CFO, Sr. VP & Member of Exec. Board||N/A||N/A||1974|
|Mr. Peter Rasmussen||VP of Fin. & Principal Accounting Officer||N/A||N/A||1969|
|Ms. Lotte Sønderbjerg||Chief Admin. Officer & Sr. VP||N/A||N/A||1961|
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone has completed Phase I clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
Ascendis Pharma A/S’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.